NYSE:RTX
NYSE:RTXAerospace & Defense

Is RTX Still a Smart Pick After Surging 35% and Raytheon Engine Deal News?

Deciding what to do with RTX stock right now? You are not alone. This American industrial heavyweight has captured plenty of investor attention in 2024, bouncing back with an impressive 34.7% gain year-to-date. In fact, over the past year, RTX has notched a total return of 35.1%. The stock has steadily climbed out of last year’s uncertainty, in part due to rebounding defense contracts and a brightening outlook in the aerospace sector. Market sentiment seems to have shifted as well. Recent...
NasdaqGS:EA
NasdaqGS:EAEntertainment

Is Now the Right Time to Consider EA After Impressive 17% Stock Rally?

If you have been keeping an eye on Electronic Arts stock lately, you are probably wondering if now is the right time to jump in, cash out, or just sit tight. EA's share price has delivered some excitement over the past year, with a solid 17% total return, and a strong showing in the past quarter, climbing nearly 17%. That is the kind of run that grabs attention. It is tempting to assume the best days are yet to come, especially when big-name franchises and major market trends are in play. But...
NasdaqCM:CELC
NasdaqCM:CELCBiotechs

Do Celcuity's (CELC) Widening Losses Reflect a Shift in Its Long-Term Growth Strategy?

On August 14, 2025, Celcuity Inc. announced its results for the second quarter and first half of 2025, reporting a net loss of US$45.27 million for the quarter and US$82.27 million for the six-month period, both wider than the prior year. The company's loss per share also increased compared to last year, highlighting heightened operating expenses and a growing financial gap. We'll explore how the deepening net losses shape Celcuity's investment narrative and what they signal about its...
NYSE:MET
NYSE:METInsurance

Assessing MetLife (MET) Valuation as Shares Quietly Rally to New Highs

MetLife (MET) has popped up on investors’ radars again, thanks to its recent run in the stock price. While there has not been a headline-grabbing event or major announcement, the steady climb in the share price has naturally raised some eyebrows among those weighing their next move. For investors tuned into the insurance sector, these kinds of slow-burn rallies can be just as interesting as splashy news. Sometimes, they are even more telling when it comes to forecasting value. Looking at the...
NYSE:RSG
NYSE:RSGCommercial Services

Does the Recent 7% Pullback Offer a Fresh Entry for Republic Services in 2025?

If you are eyeing Republic Services right now, you are certainly not alone. As one of the biggest names in the waste management game, RSG has been quietly churning out steady gains, attracting both growth seekers and investors who want some defensive stability in their portfolio. But the question a lot of us keep circling back to is, at these levels, is the stock actually undervalued or has all the upside been priced in? Recent stock price action gives us plenty to discuss. Over the last...
NasdaqGS:LRCX
NasdaqGS:LRCXSemiconductor

Is Lam Research’s Recent 21% Rally Justified After Latest Earnings Outlook?

If you have been watching Lam Research lately, you know it has been quite a ride. Whether you are an investor on the fence or simply curious about this semiconductor powerhouse, there is no denying how dynamic things have become with LRCX. Over the past three months, shares have surged more than 21% as investors have warmed to the chip sector again and shrugged off broader market jitters. Year-to-date, Lam is up a robust 36%, adding to already impressive long-term gains. What is driving this...
NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

Adaptive Biotechnologies (ADPT): How Genentech Exit Could Shift Valuation and Future Growth Strategy

If you are tracking Adaptive Biotechnologies (ADPT), the news that its strategic collaboration and license agreement with Genentech will be winding down might catch your attention. The deal, first signed in 2018 to jointly explore innovative cancer cell therapies, is set to terminate in early 2026. This will free Adaptive from previous exclusivity constraints in oncology. Notably, this change will unlock a $33.7 million boost in non-cash revenue later this year, adding detail to the...
NasdaqGS:CCB
NasdaqGS:CCBBanks

How Investors May Respond To Coastal Financial (CCB) Expanding Its Leadership Team With Fintech and Risk Experts

Earlier this month, Coastal Financial Corporation and its subsidiary, Coastal Community Bank, announced the appointment of four new executives to its leadership team, introducing key talent in product, commercial, credit, and information security roles. This leadership expansion signals a commitment to strengthening the company's digital banking capabilities and advancing its risk management practices amid ongoing growth initiatives. We'll explore how the addition of experts with fintech and...
NYSE:HRL
NYSE:HRLFood

JPMorgan Upgrade on Protein Demand Might Change The Case For Investing In Hormel Foods (HRL)

Earlier this week, JPMorgan upgraded Hormel Foods based on an anticipated increase in demand for the company's protein-focused and cleaner-label products, despite recent softness in sales volumes and profitability challenges. This analyst action stands out because it contrasts with the company's recent struggle to maintain higher sales and profit margins in a competitive market. We'll explore how JPMorgan's optimism around demand for Hormel's protein and natural ingredient offerings could...
NYSE:DGX
NYSE:DGXHealthcare

Quest Diagnostics (DGX): Exploring Valuation After Recent Share Price Pause

If you have been watching Quest Diagnostics (DGX) lately, the recent dip in its stock price might have raised an eyebrow or two. Shares edged down about 0.4% after a period of impressive year-to-date growth. While there is no headline-grabbing event behind this move, subtle shifts like this often prompt investors to step back and re-evaluate what the market may be signaling about future prospects. Looking at the bigger picture, Quest Diagnostics has quietly outperformed many of its peers...
NYSE:SYK
NYSE:SYKMedical Equipment

Are Stryker Shares Fully Priced After Strong Device Sales and Recent FDA Approvals?

If you are trying to decide what to do with Stryker stock right now, you are not alone. The company’s shares have had a busy year, climbing more than 10% over the past 12 months and sitting up over 72% year to date. That is impressive, especially considering a recent dip over the past month and an overall return of more than 100% over five years. Stryker’s ability to consistently generate revenue growth and boost its bottom line has kept investors interested, even while the broader healthcare...
NYSE:PG
NYSE:PGHousehold Products

Procter & Gamble (PG): Assessing Current Valuation After a Year of Subtle Share Declines

Procter & Gamble (PG) has turned heads after a quiet drift downward this year, with shares now sitting just below where they started twelve months ago. It is not a major announcement or earnings miss that is catching investors’ attention; rather, the subtle slide has left some wondering if the world’s biggest household products maker is setting up for a comeback or bracing for more caution from the market. On the surface, it has been an unexciting year for Procter & Gamble. The stock edged...
NasdaqGS:FTNT
NasdaqGS:FTNTSoftware

What Recent Earnings Reveal About Fortinet’s Current Value in 2025

Thinking about what to do with Fortinet stock? You are not alone in wondering whether now might be the right time to buy, hold, or steer clear. After all, the cybersecurity giant has had a rollercoaster year in the market, which has probably left many investors feeling a bit whiplashed. Over the past three months, shares have pulled back by about 25%. If you zoom out to three or even five years, the returns are nothing short of impressive: up more than 52% and 194% respectively. Even with...
NYSE:DD
NYSE:DDChemicals

How DuPont Stock’s Recent Rally and Merck Partnership Shape Its 2025 Value Prospects

If you are contemplating what your next move should be with DuPont de Nemours stock, you are definitely not alone. Investors have been trying to make sense of its latest performance, wondering whether recent ups and downs hint at a hidden bargain or newly introduced risks. Over the past three months, DuPont shares have rebounded by more than 10%, outpacing the broader market as investors responded to improved sentiment about the company’s prospects and shifting macroeconomic conditions. Even...
NYSE:FDX
NYSE:FDXLogistics

Is FedEx’s Valuation Attractive After CEO’s High-Profile China Business Trip?

If you are watching FedEx stock right now, you have probably noticed it has been a rollercoaster. After a difficult run over the past year, with the stock down about 22% in total return, many investors are asking if all the bad news is priced in or if there is still some rough air ahead. Even so, not everything about FDX is headed south. In the last three months, the stock has shown signs of life with a 4% gain, which stands out against a challenging logistics sector. Part of the recent...
NYSE:AER
NYSE:AERTrade Distributors

AerCap Holdings (AER): Evaluating Valuation After Recent Undervaluation Commentary and Profit Outlook Concerns

AerCap Holdings (NYSE:AER) has attracted investor attention after recent commentary noted its shares are trading at a price-to-earnings ratio well below that of its peers. This has led to suggestions that AerCap’s stock might be undervalued. At the same time, there are questions about the company’s profit outlook, which is uncertain due to forecasts of negative growth in the coming period. Investors face a dilemma between attractive valuation metrics and a less certain short-term financial...
NYSE:CRBG
NYSE:CRBGDiversified Financial

Corebridge Financial (CRBG): Evaluating Whether Recent Price Swings Signal an Undervalued Opportunity

Curious about whether Corebridge Financial (CRBG) deserves a spot on your radar? The company’s latest moves have not set off alarms or drawn bright headlines, but the steady attention from investors suggests there could be more beneath the surface. This might leave you wondering if the recent dip in its share price is just noise or an early sign of something bigger to come. Over the past year, Corebridge Financial’s stock has gained nearly 24%, despite losing a bit of steam this month and...
NasdaqGS:NDSN
NasdaqGS:NDSNMachinery

Nordson (NDSN): Assessing Valuation After Earnings Growth and $500M Share Buyback Expansion

If you have been tracking Nordson (NDSN), this week’s headlines probably caught your eye. The company just posted higher third-quarter sales and net income compared to last year, providing solid evidence of operational momentum. On top of that, management has approved a $500 million boost to its share buyback program, bringing total authorization to $2 billion. For investors weighing their next move, these pieces of news together signal both business resilience and a clear vote of confidence...
NYSE:XYL
NYSE:XYLMachinery

Evaluating Xylem After 21% Surge and New EPA Water Infrastructure Grants

If you are weighing what to do with Xylem stock, you are not alone. Lately, onlookers have been trying to gauge what's driving XYL's complex moves in the market. After a choppy spring, Xylem’s share price has notched up an impressive 21% gain year-to-date, and even over the last three years, the stock has delivered nearly a 49% total return. Those numbers are hard to ignore, especially if you are on the hunt for companies with a mix of steady growth and potential upside. So, what is fueling...
NYSE:ADM
NYSE:ADMFood

Archer-Daniels-Midland (ADM) Valuation in Focus After OCOchem CO2 Conversion Partnership Announcement

The recent announcement of a production partnership between Archer-Daniels-Midland (ADM) and OCOchem is certainly one for investors to pay attention to. The two companies are teaming up to build a demonstration plant at ADM’s Decatur, Illinois corn processing complex. This facility aims to turn biogenic CO2 captured from ethanol production into high-value formate molecules using OCOchem’s advanced Carbon FluX Electrolyzer technology. With construction set to begin later this year, this...
NasdaqCM:VEON
NasdaqCM:VEONWireless Telecom

How Investors May Respond To VEON (VEON) Testing Starlink Direct to Cell Satellite Integration in Ukraine

On August 12, 2025, Kyivstar, VEON Ltd.'s leading digital operator in Ukraine, completed the first field test of Starlink Direct to Cell satellite integration in eastern Europe, using 4G-enabled smartphones to exchange messages in the Zhytomyr region. This collaboration positions VEON and Kyivstar at the forefront of advanced satellite-terrestrial connectivity, opening doors to new digital services amid Ukraine's accelerating digital infrastructure needs. We will explore how Kyivstar’s...
NasdaqGS:XP
NasdaqGS:XPCapital Markets

Will XP's (XP) Earnings Momentum Sustain Its Competitive Edge in Brazil's Fintech Market?

XP Inc. announced its second quarter 2025 results on August 18, reporting revenue of R$4.46 billion and net income of R$1.32 billion, both higher than the prior year period. The company's results showed continuing earnings per share growth, with diluted EPS from continuing operations rising to R$2.46 compared to R$2.03 a year earlier. We will assess how XP Inc.'s continued growth in revenue and profit informs the broader investment narrative for the business. The end of cancer? These 26...
NasdaqGS:EXPE
NasdaqGS:EXPEHospitality

Can Expedia’s Recent 8.4% Surge Signal More Upside Ahead in 2025?

Thinking about what to do with Expedia Group stock right now? You are not alone. With shares recently closing just above the $205 mark, this travel tech giant is commanding attention from investors looking for both value and growth. Over the past year, Expedia Group has put up an impressive 55% total return, helping to erase memories of the industry's pandemic lows and rekindling excitement about what the future might hold. In the shorter term, the story has been mixed. There has been a minor...